CO2023003242A2 - Vacuna contra el coronavirus y procedimiento para la preparación de la misma - Google Patents

Vacuna contra el coronavirus y procedimiento para la preparación de la misma

Info

Publication number
CO2023003242A2
CO2023003242A2 CONC2023/0003242A CO2023003242A CO2023003242A2 CO 2023003242 A2 CO2023003242 A2 CO 2023003242A2 CO 2023003242 A CO2023003242 A CO 2023003242A CO 2023003242 A2 CO2023003242 A2 CO 2023003242A2
Authority
CO
Colombia
Prior art keywords
preparation
cov
sars
vaccine
present
Prior art date
Application number
CONC2023/0003242A
Other languages
English (en)
Inventor
Krishna Murthy Ella
Deepak Kumar
Original Assignee
Bharat Biotech Int Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bharat Biotech Int Ltd filed Critical Bharat Biotech Int Ltd
Publication of CO2023003242A2 publication Critical patent/CO2023003242A2/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/12Viral antigens
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/12Viral antigens
    • A61K39/215Coronaviridae, e.g. avian infectious bronchitis virus
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/39Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/04Immunostimulants
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/51Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525Virus
    • A61K2039/5252Virus inactivated (killed)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/555Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505Inorganic adjuvants
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011Details
    • C12N2770/20011Coronaviridae
    • C12N2770/20022New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011Details
    • C12N2770/20011Coronaviridae
    • C12N2770/20034Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011Details
    • C12N2770/20011Coronaviridae
    • C12N2770/20051Methods of production or purification of viral material
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011Details
    • C12N2770/20011Coronaviridae
    • C12N2770/20051Methods of production or purification of viral material
    • C12N2770/20052Methods of production or purification of viral material relating to complementing cells and packaging systems for producing virus or viral particles
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011Details
    • C12N2770/20011Coronaviridae
    • C12N2770/20061Methods of inactivation or attenuation
    • C12N2770/20063Methods of inactivation or attenuation by chemical treatment

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Microbiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Mycology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pulmonology (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

La presente invención se refiere a una vacuna y a un tratamiento para la infección (COVID-19) provocada por el nuevo coronavirus (SARS-CoV-2) en mamíferos. En particular, la invención se refiere a una vacuna contra el coronavirus y al procedimiento para la preparación de la misma. Más particularmente, la presente invención divulga la preparación de una vacuna contra el coronavirus que comprende un SARS-CoV-2 purificado inactivado como principio activo. La presente invención también describe un procedimiento para la preparación del virus SARS-CoV-2 muerto-inactivado que es usado como antígeno en la composición de vacuna. La presente invención se refiere además al procedimiento de preparación de antígenos que incluye la inactivación y la purificación del virus, la preparación de la vacuna contra el SARS-CoV-2, la composición, la formulación y el uso de la misma para provocar una respuesta inmunitaria contra el SARS-CoV-2 en mamíferos, y que también es adecuada para inmunizar sujetos humanos.
CONC2023/0003242A 2020-08-21 2023-03-16 Vacuna contra el coronavirus y procedimiento para la preparación de la misma CO2023003242A2 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN202041007559 2020-08-21
PCT/IN2021/050806 WO2022038642A1 (en) 2020-08-21 2021-08-21 Coronavirus vaccine and method for preparation thereof

Publications (1)

Publication Number Publication Date
CO2023003242A2 true CO2023003242A2 (es) 2023-03-27

Family

ID=80322935

Family Applications (1)

Application Number Title Priority Date Filing Date
CONC2023/0003242A CO2023003242A2 (es) 2020-08-21 2023-03-16 Vacuna contra el coronavirus y procedimiento para la preparación de la misma

Country Status (5)

Country Link
US (1) US20240050557A1 (es)
EP (1) EP4200409A1 (es)
BR (1) BR112023003190A2 (es)
CO (1) CO2023003242A2 (es)
WO (1) WO2022038642A1 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115011566B (zh) * 2022-05-25 2024-01-23 辽宁成大生物股份有限公司 一种人用狂犬病疫苗中残留dna的去除方法
WO2023250111A1 (en) 2022-06-22 2023-12-28 Flagship Pioneering Innovations Vi, Llc Combination therapies for the treatment of viral infections
US11654121B1 (en) 2022-06-22 2023-05-23 Flagship Pioneering Innovations Vi, Llc Combination therapies for the treatment of viral infections
WO2024029469A1 (ja) * 2022-08-03 2024-02-08 Kmバイオロジクス株式会社 不活化SARS-CoV-2ワクチンの製造方法、及び不活化SARS-CoV-2ワクチン、並びにSARS-CoV-2又は不活化SARS-CoV-2の精製方法、及びSARS-CoV-2抗原組成物又は不活化SARS-CoV-2抗原組成物

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108601825B (zh) * 2015-07-16 2023-06-20 巴拉特生物技术国际有限公司 疫苗组合物
CN111426839A (zh) * 2020-03-19 2020-07-17 深圳市疾病预防控制中心 用于2019新型冠状病毒的检测试纸及制备工艺
CN111471103A (zh) * 2020-03-20 2020-07-31 唐山怡安生物工程有限公司 一种新冠病毒(2019-nCOV)的异源抗体及其制备方法
CN111437384A (zh) * 2020-04-07 2020-07-24 四川骋誉生物制品有限公司 用于预防covid-19的蝙蝠源性冠状病毒疫苗

Also Published As

Publication number Publication date
BR112023003190A2 (pt) 2023-03-28
EP4200409A1 (en) 2023-06-28
US20240050557A1 (en) 2024-02-15
WO2022038642A1 (en) 2022-02-24

Similar Documents

Publication Publication Date Title
CO2023003242A2 (es) Vacuna contra el coronavirus y procedimiento para la preparación de la misma
MX2022015132A (es) Vacunas combinadas a base de acidos nucleicos.
JP5809560B2 (ja) インフルエンザに対して使用するためのワクチン組成物
PE20211545A1 (es) Dosis unitaria de vacuna contra el dengue y administracion de esta
CO6270337A2 (es) Vacuna viva avirulenta de mycoplama hyopneumoniae con adyuvante
UY32208A (es) Uso de antigeno de mycoplasma bovis
AR108829A1 (es) Vacuna contra virus de bronquitis infecciosa
BR112021021637A2 (pt) Vacina de subunidade para tratamento ou prevenção de uma infecção do trato respiratório
CL2021002582A1 (es) Vacunas contra el circovirus porcino tipo 3 (pcv3), su producción y usos
AR093185A1 (es) Virus prrs (sindrome reproductivo y respiratorio porcino) que induce al interferon tipo i en celulas susceptibles
NZ587798A (en) Improvements in the preparation of influenza virus vaccine antigens utilising a phosphate buffer
MX2023003784A (es) Peptido derivado de proteina de sars-cov-2 y vacuna que lo contiene.
CO2022012272A2 (es) Vacunas contra el coronavirus y métodos de uso
CL2007002710A1 (es) Formulacion inmunogenica que confiere proteccion contra la infeccion o patologia causada por el virus respiratorio sincicial (vrs) que comprende una cepa recombinante atenuada de mycobacterium; y uso de la formulacion inmunogenica para preparar una vacuna para prevenir, tratar o atenuar infecciones del vrs.
CO6280408A2 (es) Vacuna de virus de la lengua azul y composiciones inmunogenicas procedimientos de uso y procedimeintos de la produccuion de la misma
AR082577A1 (es) Vacunas de virus varicela zoster inactivado, metodos de produccion y uso de las mismas
JP6985384B2 (ja) 弱毒変異型ジカウイルスを含むワクチン組成物
BR112022019207A2 (pt) Composições de vacina para coronavírus e métodos de uso das mesmas
BR112016012435A8 (pt) vacina, e, usos de uma proteína orf2 recombinantemente expressada do circovírus porcino tipo 2
MX2023005221A (es) Composiciones inmunogenicas para uso en vacunas neumococicas.
AR120887A1 (es) Uso de formulación inmunogénica bcg que expresa una proteína de virus respiratorio sincicial contra hmpv
CO2022002493A2 (es) Nanoemulsion de ácido 18p-glicirretínico
BR112022019876A2 (pt) Composições virucidas, composição farmacêutica, método de desinfecção e/ou esterilização, dispositivo e uso das composições virucidas
BR112022010204A2 (pt) Derivado do anel de piridina fusionado, método de preparação para o mesmo e uso farmacêutico do mesmo
AR109291A1 (es) Clon de adnc del virus del síndrome reproductivo y respiratorio porcino y usos del mismo